IPCALAB - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.7
| Stock Code | IPCALAB | Market Cap | 38,809 Cr. | Current Price | 1,530 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 38.6 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.3 % |
| ROE | 12.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,501 ₹ | DMA 200 | 1,451 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 55.8 | MACD | 9.09 | Volume | 1,38,477 | Avg Vol 1Wk | 1,86,182 |
| Low price | 1,252 ₹ | High price | 1,624 ₹ | PEG Ratio | -30.2 | Debt to equity | 0.11 |
| 52w Index | 74.8 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 30.2 |
📊 Ipca Laboratories (IPCALAB) shows moderate potential for swing trading. The RSI at 55.8 indicates balanced momentum, while the MACD (9.09) is positive, suggesting bullish signals. The current price (₹1,530) is above both the 50 DMA (₹1,501) and 200 DMA (₹1,451), reflecting short-term strength. Fundamentals are decent with ROCE (17.3%) and ROE (12.4%), but the high P/E (38.6) compared to industry PE (30.2) and negative PEG ratio (-30.2) raise valuation concerns. PAT has remained flat sequentially (₹305 Cr. → ₹303 Cr.), limiting earnings momentum.
💡 Optimal Entry Price: Around ₹1,500–₹1,520, near DMA support.
📈 Exit Strategy (if already holding): Consider booking profits near ₹1,600–₹1,620, close to the recent high.
✅ Positive
- Price trading above both 50 DMA and 200 DMA shows technical strength.
- ROCE (17.3%) and ROE (12.4%) reflect steady efficiency.
- Low debt-to-equity ratio (0.11) ensures financial stability.
- EPS of ₹31.7 supports earnings consistency.
⚠️ Limitation
- High P/E ratio (38.6) compared to industry PE (30.2), suggesting overvaluation.
- Negative PEG ratio (-30.2) highlights weak growth relative to valuation.
- Sequential PAT stagnation (₹305 Cr. → ₹303 Cr.).
📉 Company Negative News
- Flat quarterly PAT indicates limited earnings momentum.
- Valuation stretched compared to peers.
📈 Company Positive News
- Quarterly profit variation shows 13.4% YoY growth.
- FII (+0.01%) and DII (+0.14%) holdings increased, signaling investor confidence.
🏭 Industry
- Industry PE at 30.2 vs. IPCALAB’s PE of 38.6 highlights relative overvaluation.
- Pharmaceutical sector remains resilient with long-term demand drivers.
🔎 Conclusion
IPCALAB is technically strong but fundamentally overvalued. Swing traders may enter near ₹1,500–₹1,520, targeting exits around ₹1,600–₹1,620. While earnings growth is modest, sector resilience and technical support make it a cautious but viable swing trade candidate.